Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px
Document › Details

CureVac AG. (5/19/17). "Press Release: CureVac to Present at Upcoming International Investor Conferences". Tübingen.

Organisations Organisation CureVac AG
  Group CureVac (Group)
  Organisation 2 UBS (Group)
Products Product UBS Global Healthcare Conference 2017 New York
  Product 2 BioEquity Europe 2017 Paris
Index terms Index term CureVac–UBS: investor conference, 201705 supply service CureVac presents at UBS Global Healthcare Conference NY
  Index term 2 CureVac–Informa: investor conference, 201705 supply service CureVac presents at BioEquity Europe 2017 in Paris
Persons Person Kemula, Pierre (CureVac 201610– CFO before Pixium Vision + Ipsen + Roland Berger)
  Person 2 Haas, Franz-Werner (CureVac 201206– Chief Corporate Officer before Sygnis + Lion BIoscience)

CureVac AG, the most clinically ad-vanced mRNA company, today announced that the company will present at two upcoming international investor conferences: UBS 2017 Global Healthcare Confer-ence in New York, NY; and Bio€quity Europe in Paris, France.

Executives from CureVac will provide an overview of the company’s business, in-dustry-leading mRNA technology platform, and clinical-stage product pipeline during each presentation and will be available to participate in one-on-one meet-ings with investors who are registered to attend each conference.

Event: UBS 2017 Global Healthcare Conference
Presenter: Pierre Kermula, Chief Financial Officer
Date: Monday, May 22, 2017
Time: 2:30 – 3:00 pm, ET
Location: Grand Hyatt, New York, NY – Ballroom IV

Event: Bio€quity Europe
Presenter: Dr. Franz-Werner Haas, Chief Corporate Officer
Date: Monday, May 22, 2017
Time: 3:40 – 4:00 pm, CET
Location: Marriott Rive Gauche, Paris, France– Forum EF, Level -1

About CureVac AG

Founded in 2000 as a spin-off from the University of T?bingen in Germany, CureVac is a technology leader in the development of drugs that are based on the molecule Messenger RNA (mRNA). The fully integrated biopharmaceutical Ccompa-ny has more than 17 years of expertise in handling and optimizing this versatile molecule for medical purposes.

The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the de-velopment of cancer therapies, prophylactic vaccines and molecular therapies.

Since its inception, strongly backed by SAP founder Dietmar Hopp’s dievini CureVac has received approximately $370 million (€355 million) in equity invest-ments including an investment of the Bill & Melinda Gates Foundation of $ 52million in 2015. CureVac has entered into various collaborations with multina-tional corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI.
In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac started the establishment and construc-tion of industrial scale production facilities.

For more information, please visit


Media Contacts

Verena Lauterbach, Senior Manager Communications
CureVac AG, Tübingen, Germany
T: +49 (0) 7071 9883 1756

Andrew Mielach, Vice President
Tiberend Strategic Advisors, New York
T: +1 212 375 2694

Record changed: 2017-07-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for CureVac (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top